Novo Nordisk disclosed a cyberattack in which attackers accessed a limited number of internal IT systems and copied non-public data tied to some clinical trial participants and healthcare professionals. The stolen clinical trial information included pseudonymized patient identifiers rather than direct identifiers such as names, but it still covered sensitive fields including trial participation details, sex or gender, year of birth, biomarkers, health or immunogenicity data, and lifestyle factors such as smoking status, alcohol use, and BMI.
The company said healthcare professional contact and registration details were also exposed, raising the risk of targeted phishing and impersonation attempts over email, phone, and WhatsApp. Novo Nordisk took affected internal systems offline as a precaution, brought in external cybersecurity experts to investigate, and said core business operations were not impacted, while the total number of affected individuals and the full scope of the breach remain under investigation.

Mallory correlates global threat intelligence with your attack surface — know if you’re exposed before adversaries strike.
7 events from the most recent confirmed update back to the earliest known activity.
Novo Nordisk said it notified Danish regulators after discovering the intrusion into its internal IT infrastructure. The company also said it engaged external cybersecurity experts to investigate the incident.
A report said threat actor FulcrumSec leaked Novo Nordisk data after an alleged $2.5 million demand went unpaid. This represented a post-disclosure escalation tied to the previously disclosed cybersecurity incident.
DataBreaches reportedly received Signal messages from another person claiming they had also hacked Novo Nordisk and demanded $50 million. This introduced a separate extortion claim beyond FulcrumSec's previously reported $25 million demand.
SecurityWeek reported that FulcrumSec claimed responsibility for the Novo Nordisk intrusion, alleging it first gained access in March via a GitHub access token and then used cloned repositories to locate additional credentials. The group claimed it stole about 1.3 TB of data, including intellectual property, and said it demanded a $25 million ransom before threatening to leak the data.
As part of its response to the breach, Novo Nordisk took some internal systems offline as a precaution and engaged external cybersecurity experts to investigate. The company stated that core business operations were not affected and that the full scope of the incident was still under investigation.
Novo Nordisk disclosed that attackers accessed a limited number of internal IT systems and copied non-public data related to some clinical trial participants and healthcare professionals. The company said the participant data was pseudonymized and did not include direct identifiers, but included sensitive health-related and trial information, while healthcare professional data created phishing and impersonation risks.
Sysdig reported that FulcrumSec has been active since at least September 2025 and has claimed roughly 25 victims across 11 countries. The report characterized the group as a cloud-focused extortion actor that steals data without deploying ransomware.
Vulnerabilities, threat actors, malware, products, organizations, and breaches Mallory has linked to this story.
28 references tracked. Mallory keeps watching after this page renders.
webflow.sysdig.com
Open sourcewebflow.sysdig.com
Open sourceteiss.co.uk
Open sourcecybelangel.com
Open sourcetheregister.com
Open sourcenovonordisk.com
Open sourcedatabreaches.net
Open sourcedatabreaches.net
Open sourceMap indicators from this story to your assets and identify affected systems in minutes.
Every observed campaign, victim, and pivot linked to actors named in this story.
Malware, exploits, and IOCs connected to the activity described here.
YARA, Sigma, and Snort rules deployed to your SIEM as soon as they’re published.
Get matching new stories delivered to your team as they break — not the next morning.
Ask questions about this story and take action on the answers.